0001193125-24-064791.txt : 20240311 0001193125-24-064791.hdr.sgml : 20240311 20240311160555 ACCESSION NUMBER: 0001193125-24-064791 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240311 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 24737979 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 d786050d8k.htm 8-K 8-K
ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2024-03-11 2024-03-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2024

 

 

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-50768   06-1376651

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

12830 El Camino Real, Suite 400

San Diego, California

  92130
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 558-2871

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 8.01

Other Events.

On March 11, 2024, Acadia Pharmaceuticals Inc. (the “Company”) announced top-line results of the Company’s Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. The study did not meet its primary endpoint. The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Acadia Pharmaceuticals Inc.
Dated: March 11, 2024     By:  

/s/ Jennifer J. Rhodes

      Jennifer J. Rhodes
      Executive Vice President, Chief Legal Officer & Secretary
EX-101.SCH 2 acad-20240311.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 acad-20240311_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 acad-20240311_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 11, 2024
Cover [Abstract]  
Entity Registrant Name ACADIA PHARMACEUTICALS INC
Amendment Flag false
Entity Central Index Key 0001070494
Document Type 8-K
Document Period End Date Mar. 11, 2024
Entity Incorporation State Country Code DE
Entity File Number 000-50768
Entity Tax Identification Number 06-1376651
Entity Address, Address Line One 12830 El Camino Real
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 558-2871
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol ACAD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports acad-20240311.xsd acad-20240311_lab.xml acad-20240311_pre.xml d786050d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d786050d8k.htm": { "nsprefix": "acad", "nsuri": "http://www.acadia-pharm.com/20240311", "dts": { "schema": { "local": [ "acad-20240311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "acad-20240311_lab.xml" ] }, "presentationLink": { "local": [ "acad-20240311_pre.xml" ] }, "inline": { "local": [ "d786050d8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-11_to_2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d786050d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-11_to_2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d786050d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.acadia-pharm.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-064791-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-064791-xbrl.zip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end XML 16 d786050d8k_htm.xml IDEA: XBRL DOCUMENT 0001070494 2024-03-11 2024-03-11 ACADIA PHARMACEUTICALS INC false 0001070494 8-K 2024-03-11 DE 000-50768 06-1376651 12830 El Camino Real Suite 400 San Diego CA 92130 (858) 558-2871 false false false false Common Stock, par value $0.0001 per share ACAD NASDAQ false